Han Kim

Company: Bolt Biotherapeutics

Job title: s

Seminars:

Potent next-gen ISAC targeting Claudin 18.2 12:30 pm

Efficacy in low-antigen-density tumors Demonstrated superiority to ADCs in preclinical studies Immunologic memory with epitope spreading provides promise of durable responses and prevents recurrence MTD ≥ 12 mg/kg in NHPs with differentiated toxicology profile from cytotoxic ADCs Preparing for first-in-human clinical trialRead more

day: Conference Day 2